The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|March 30, 2023
Trialbee Partners With Savvy Cooperative
Advertisement
Trialbee has announced a strategic partnership with Savvy Cooperative. This partnership primarily addresses two pain points for patients—the challenge of finding appropriate clinical trials and the lack of opportunity to express their experiences to the industry as consumers of healthcare—an area still ripe for disruption.
As a practical example, Savvy Cooperative members will be introduced to specific clinical trials with an invitation to participate in pre-screening and referral to sites via the Trialbee Honey platform. At the end of the process, all potential participants who come through Honey, regardless of channel, will be invited to join the #AskPatients™ community to share their experiences for future research. While the collaboration is inclusive of all members in the Savvy community, lupus and multiple sclerosis have been selected as pilot indications to demonstrate the power of the partnership as these patients are simultaneously active yet traditionally under recruited.
Reference
Trialbee Partners with Savvy Cooperative to Bring the Voice of the Patient into Clinical Trials Earlier. (2023, March 29). Cision PRWeb.
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5